ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to characterize the performance of the WATCHMAN LAA Closure Device in atrial fibrillation patients for which long term warfarin therapy is contraindicated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

NCT01182441

Atrial Fibrillation Stroke

COMPLETED PHASE3

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology

NCT02702271

Atrial Fibrillation

COMPLETED NA

Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI

NCT02492230

Myocardial Infarction

UNKNOWN PHASE2

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

NCT00129545

Atrial Fibrillation Stroke

COMPLETED PHASE2/PHASE3

Registry on WATCHMAN Outcomes in Real-Life Utilization

NCT01972282

Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

WATCHMAN

non-valvular atrial fibrillation patients contraindicated to warfarin

Group Type EXPERIMENTAL

WATCHMAN

Intervention Type DEVICE

WATCHMAN LAA Closure Device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WATCHMAN

WATCHMAN LAA Closure Device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* paroxysma, persistent, or permanent non-vlavular atrial fibrillation
* contraindicated to warfarin
* eligible for clopidogrel, ticlopdine, heparin, or aspirin
* CHADS score 1 or greater